Regenxbio Faces Class Action Over Alleged Misrepresentation of RGX-111 Safety and Efficacy

Regenxbio Faces Class Action Lawsuit Amidst Controversy Over RGX-111

Regenxbio, a biopharmaceutical company known for its pioneering gene therapies, is currently embroiled in a class action lawsuit filed by Robbins LLP on behalf of shareholders. The lawsuit targets investors who acquired shares within a specified timeframe from February 9, 2022, to January 27, 2026, alleging that the company misrepresented the safety and efficacy of its drug candidate, RGX-111. The lawsuit asserts that Regenxbio touted RGX-111 as a leading adeno-associated virus (AAV) therapeutic for the treatment of mucopolysaccharidosis type I (MPS I), pointing to positive findings from Phase I/II studies and its Fast Track designation from the FDA as evidence of its promising potential.

However, the lawsuit claims that Regenxbio was aware of significant safety concerns related to RGX-111, specifically the elevated risk of central nervous system (CNS) neoplasm, which raises alarm over the company’s transparency with investors. The situation escalated dramatically when, in November 2023, Regenxbio announced a decision to downscale its RGX-111 development program, heightening concerns among stakeholders. The turning point for the company came on January 28, 2026, when the FDA placed a clinical hold on RGX-111 after reports of a neoplasm in a trial participant surfaced, resulting in another hold on the closely related RGX-121.

Following these developments, Regenxbio witnessed a significant drop in stock value, underscoring the potential financial ramifications for investors. The company's stock plummeted by 17.8%, from $13.41 to $11.01 in a single day, reflecting the heightened investor uncertainty. Those who wish to participate in the class action as lead plaintiffs must submit their applications by April 14, 2026. Notably, the complaint emphasizes that plaintiffs will incur no fees or expenses since representation is provided on a contingency basis, enabling broader access for affected shareholders seeking justice.

In related news, Regenxbio's recent challenges highlight ongoing concerns surrounding gene therapy approaches and the regulatory landscape for such treatments. As the biotechnology industry continues to evolve, the repercussions of this lawsuit may reverberate beyond Regenxbio, potentially impacting investor confidence across the sector. The scrutiny around RGX-111 illuminates critical issues related to patient safety and corporate accountability within the rapidly advancing field of gene therapy.